Masimo Corp - MASI STOCK NEWS

Masimo (NASDAQ: MASI) is set to present at the Stifel Virtual Healthcare Conference on November 17, 2020, at 2:40 p.m. Eastern Time. Live access to the presentation will be available via webcast on the Masimo website, with a replay offered afterward. Known for its advanced medical monitoring technologies, Masimo’s innovations, such as SET pulse oximetry, have significantly improved patient outcomes and reduced healthcare costs. The company’s products are used globally, impacting over 100 million patients and assisting healthcare professionals in critical care scenarios.

Masimo (NASDAQ: MASI) recently published a study in Blood Transfusion highlighting the advantages of utilizing its SpHb technology within a patient blood management (PBM) program for postoperative cancer patients. The study demonstrated a significant increase in transfusion appropriateness, rising from 38% to 79% with the implementation of SpHb monitoring. Additionally, the average number of red blood cell units transfused per patient declined from 1.8 to 1.3. The researchers emphasize that structured PBM programs can improve transfusion quality and quantity.

Masimo (NASDAQ: MASI) has announced that its wearable, tetherless vital signs monitor, Radius VSM™, has received CE marking and is being launched in select European markets. This versatile device can monitor various physiological parameters, including continuous pulse oximetry and noninvasive blood pressure. Radius VSM features a modular design suited for different patient needs and encourages mobility for faster recovery. It offers wireless communication with bedside monitors and EMR systems, enhancing patient care, especially during COVID-19. CEO Joe Kiani expressed excitement for its European rollout and future global availability.

Masimo (NASDAQ: MASI) reported strong Q3 2020 results, with total revenue reaching $278.1 million, a 21.4% increase from Q3 2019. Product revenue rose by 21.5%, while noninvasive technology shipments surged 150% year-over-year. GAAP net income was $49.4 million ($0.85 per share), compared to $49.1 million ($0.86) in 2019. The company updated its full-year 2020 guidance, projecting total revenue of $1,128.0 million and diluted EPS of $3.77. Masimo cited ongoing investments to address COVID-19 challenges as a key factor in its growth.

Masimo (NASDAQ: MASI) plans to release its third quarter 2020 financial results on October 27, 2020, after market close. CEO Joe Kiani and CFO Micah Young will host a conference call at 1:30 p.m. PT to discuss the results. Interested participants can register for the call through a provided link. Masimo is a leading medical technology company known for its innovative monitoring solutions that aim to enhance patient outcomes and reduce healthcare costs. The company has a significant presence in hospitals, particularly with its widely used Masimo SET pulse oximetry technology.

Masimo (NASDAQ: MASI) has announced that Dr. Augusto Sola, Vice President of Medical Affairs for Neonatology, has received the prestigious 2020 Pioneer Award from the American Academy of Pediatrics (AAP). This award honors Dr. Sola's significant contributions in neonatology, particularly through the use of Masimo SET® technology, which has greatly improved health outcomes for newborns. His work has been instrumental in reducing neonatal blindness and enhancing understanding of neonatal care.

Masimo (NASDAQ: MASI) presented findings from a retrospective study at ANESTHESIOLOGY 2020, demonstrating that the Oxygen Reserve Index (ORi) could effectively predict postoperative oxygen therapy needs in children with obstructive sleep apnea syndrome (OSAS) undergoing tonsillectomy. The study involved 45 pediatric patients, revealing that those requiring therapy had lower mean ORi and SpO2 values (0.28 and 93%, respectively) compared to those who did not (0.64 and 97%). ORi's sensitivity and specificity for predicting the necessity of therapy were calculated at 0.815 and 0.931, respectively. Note that ORi is not FDA-cleared and is unavailable in the U.S.

Masimo Corporation (Nasdaq: MASI) announced preliminary financial results for Q3 2020, projecting product revenue between $274 million and $278 million, representing a growth of 19.7% to 21.4% year-over-year. For the full year 2020, Masimo expects product revenue to be between $1,124 million and $1,128 million, reflecting a growth of 20.0% to 20.5% compared to 2019. A conference call is scheduled for October 27, 2020, to discuss complete financial results and guidance.

Masimo (NASDAQ: MASI) has launched the Radius Tº™ Continuous Thermometer, a wearable device that continuously monitors body temperature and sends data to a smartphone app. This innovation aims to enhance patient care by providing real-time temperature trends without interrupting daily activities, such as sleep. The Radius Tº sensor offers laboratory-accurate measurements within ±0.1ºC and is designed for use in various age groups. While not FDA 510(k) cleared, it is CE marked and marketed under the FDA’s COVID-19 enforcement policy.